IP Library Granted Patent US 8,277,416
Granted Patent B2
US 8,277,416 · App. 11/073,902 · Granted Oct 2, 2012

Powerhead of a power injection system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,277,416
App. No.
11/073,902
Granted
Oct 2, 2012
Kind
B2
Abstract

A contrast media injection system includes detects the absolute position of the syringe ram using a non-contact sensor. A series of magnets and Hall-Effect sensors may be used or an opto-reflective system. Illuminated knobs that are connected to the drive mechanism for the syringe ram rotate with the drive and provide visual feedback on operation through the illumination. Analog Hall-Effect sensors are used to determine the presence or absence of magnets that identify the type of faceplate being used. The faceplates include control electronics, connected to the powerhead through connectors, which may be interchangeably used by the two faceplates. The faceplate electronics include detectors for automatically detecting the capacity of pre-filled syringes. Additional features include using historical data to provide optimum pressure limit values during an injection protocol, a removable memory device for storing and transferring information such as injection protocols and injector statistics, and password protection of such protocols.

Claims (22)

1. A contrast media injector system comprising:

a drive mechanism movable and engageable to a fluid container to fill or expel fluid therein;

circuitry for controlling said drive mechanism in a programmed manner to effect an injection into a patient; and

a memory, said circuitry interacting with said memory to store information into and retrieve information from said memory relating to injection sequences to be carried out by said drive mechanism, said memory associating at least a first injection sequence with authentication data, said circuitry being configured to:

allow retrieval of said first injection sequence from said memory prior to requiring any said operator authentication by reference to said authentication data;

after said first injection sequence has been retrieved from said memory and still prior to requiring any said operator authentication by reference to said authentication data, to allow said first injection sequence to be modified into a first modified injection sequence;

after said first injection sequence has been modified, to allow said first injection sequence to be overwritten in said memory by said first modified injection sequence, but only after requiring said operator authentication by reference to said authentication data;

allow storage of said first modified injection sequence in said memory without requiring said operator authentication and without overwriting said first injection sequence in said memory.

2. The contrast media injector system of claim 1 , wherein each said injection sequence comprises a stored protocol.

3. The contrast media injector system of claim 1 , wherein said authentication data comprises a password.

4. The contrast media injector system of claim 1 , wherein said circuitry further allows use of said modification of said first injection sequence by said contrast media injector system without requiring said operator authentication.

5. A contrast media injector system comprising:

a drive mechanism movable and engageable to a fluid container to fill or expel fluid therein;

circuitry for controlling said drive mechanism in a programmed manner to effect an injection into a patient; and

a memory, said circuitry interacting with said memory to store information into and retrieve information from said memory relating to injection sequences to be carried out by said drive mechanism, said memory associating at least a first injection sequence with authentication data, said circuitry being configured to:

allow retrieval of said first injection sequence from said memory prior to requiring any said operator authentication by reference to said authentication data;

after said first injection sequence has been retrieved from said memory and still prior to requiring any said operator authentication by reference to said authentication data, to allow said first injection sequence to be modified into a first modified injection sequence;

after said first injection sequence has been modified, to allow said first injection sequence to be overwritten in said memory by said first modified injection sequence, but only after requiring said operator authentication by reference to said authentication data;

after said first injection sequence has been modified and prior to requiring any said operator authentication by reference to said authentication data, to allow said first modified injection sequence to be executed by said injector system; and

allow storage of said first modified injection sequence in said memory without providing said authentication data so long as said first modified injection sequence is identified by a different name than said first injection sequence.

6. The contrast media injector system of claim 5 , wherein each said injection sequence comprises a stored protocol.

7. The contrast media injector system of claim 5 , wherein said authentication data comprises a password.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 037172/0094 →